Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | M9140 |
Synonyms | |
Therapy Description |
M9140 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CEACAM5 linked to the topoisomerase I inhibitor exatecan, which potentially induces antitumor activity (Ann Oncol (2024) 35 (Suppl_2): S466; J Clin Oncol (2024) 42:16_suppl, 3000). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M9140 | M-9140|M 9140 | CEACAM5 Antibody 8 | M9140 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CEACAM5 linked to the topoisomerase I inhibitor exatecan, which potentially induces antitumor activity (Ann Oncol (2024) 35 (Suppl_2): S466; J Clin Oncol (2024) 42:16_suppl, 3000). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05464030 | Phase I | M9140 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors | Recruiting | USA | ESP | CAN | 2 |